Pfizer Corporation

Cultor Corporation

Bishop Wlodecki

Gene M Bright

Jeffrey W Raggon

Gordon D Gruetzmacher

Michael Aaron Brodney

An aminomethylpyridyloxymethyl/benzisoxazole substituted azabicyclic compound of formula I, pharmaceutical composition comprising same, and a method of treating one or more CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression, wherein formula I is or a pharmaceutically acceptable salt or thereof, wherein Z is wherein Y is methylene; X is oxygen; n is 0; Rand Rare each hydrogen or halogen; and Rand Rtogether with the nitrogen atom to which they are attached form i) a saturated non-aromatic 3 to 7 membered monocyclic ring, said ring i) being unsubstituted or substituted or substituted with one or more (C&#x2013;C)alkyl, (C&#x2013;C)alkoxy(C&#x2013;C)alkyl, or hydroxy groups.

Pyridyloxymethyl and benzisoxazole azabicyclic derivatives

The present invention relates to compounds of Formula I,wherein R, R, R, R, and n are as defined, and to pharmaceutically acceptable salts of said compounds. Compounds of Formula I have activity in agonizing 5HT7 receptors and are useful in treating, for example, disorders that can be treated by modulating circadian rhythms.

Quinoline derivatives

There is disclosed a low calorie fat substitute comprising a sorbitol fatty acid ester with a degree of substitution of about five fatty acid groups. Foodstuffs containing the sorbitol ester are also disclosed. Processes for preparing the sorbitol fatty acid esters are also disclosed.

Low calorie fat substitute

There is disclosed a low calorie fat substitute comprising a sorbitol fatty acid ester with a degree of substitution of about four fatty acid groups. Foodstuffs containing the sorbitol tetraester are also disclosed.

Growing community of inventors

Preston, CT, United States of America

Bishop Wlodecki